drugset / Trial / NCT06929663

A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors

NCT06929663

Phase 1 Recruiting 48 enrolled Akeso
NaSequentialOpen-labelTreatment

Summary

This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.

Timeline

Start
2025-07-02
Primary completion
2026-11-05
Completion
2027-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AK146D1 Unknown

Indications